Short-Term Effects of Elexacaftor/Tezacaftor/Ivacaftor Combination on Glucose Tolerance in Young People With Cystic Fibrosis—An Observational Pilot Study

Effect of CFTR modulator therapy on cystic fibrosis-related diabetes

(2021) Holly Gaines et al.   JOURNAL OF DIABETES AND ITS COMPLICATIONS

Early Diagnosis and Intervention in Cystic Fibrosis: Imagining the Unimaginable

(2021) Andrea M. Coverstone et al.   Frontiers in Pediatrics

Lumacaftor/ivacaftor in cystic fibrosis: effects on glucose metabolism and insulin secretion

(2021) C. Colombo et al.   JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION

CFTR Deficiency Affects Glucose Homeostasis via Regulating GLUT4 Plasma Membrane Transportation

(2021) Junzhong Gu et al.   Frontiers in Cell and Developmental Biology

A Phase 3 Open-Label Study of ELX/TEZ/IVA in Children 6 Through 11 Years of Age With CF and at Least One F508del Allele

(2021) Edith T. Zemanick et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Correction of sensor crosstalk error in Exhalyzer D multiple-breath washout device significantly impacts outcomes in children with cystic fibrosis

(2021) Florian Wyler et al.   JOURNAL OF APPLIED PHYSIOLOGY

The effect of elexacaftor/tezacaftor/ivacaftor (ETI) on glycemia in adults with cystic fibrosis

(2021) Kevin J. Scully et al.   Journal of Cystic Fibrosis

Continuous Glucose Monitoring as a Valuable Tool in the Early Detection of Diabetes Related to Cystic Fibrosis

(2021) Bojana Gojsina et al.   Frontiers in Pediatrics

Long-Term Outcomes in Real Life of Lumacaftor–Ivacaftor Treatment in Adolescents With Cystic Fibrosis

(2021) Stéphanie Bui et al.   Frontiers in Pediatrics

Effect of one-year lumacaftor–ivacaftor treatment on glucose tolerance abnormalities in cystic fibrosis patients

(2020) Bastien Misgault et al.   Journal of Cystic Fibrosis

Hypoglycemia and Islet Dysfunction following Oral Glucose Tolerance Testing in Pancreatic Insufficient Cystic Fibrosis

(2020) Marissa J Kilberg et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for ≥24 Weeks in People With CF and ≥1 F508del Allele: Interim Results of an Open-Label Phase Three Clinical Trial

(2020) Matthias Griese et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

From Ivacaftor to Triple Combination: A Systematic Review of Efficacy and Safety of CFTR Modulators in People with Cystic Fibrosis

(2020) Andrea Gramegna et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Lumacaftor/ivacaftor therapy fails to increase insulin secretion in F508del/F508del CF patients

(2020) Amir Moheet et al.   Journal of Cystic Fibrosis

Multiple breath washout quality control in the clinical setting

(2020) Bettina S. Frauchiger et al.   PEDIATRIC PULMONOLOGY

Functional Profiling of CFTR-Directed Therapeutics Using Pediatric Patient-Derived Nasal Epithelial Cell Models

(2020) Jeffrey KiHyun Park et al.   Frontiers in Pediatrics

Disease progression in patients with cystic fibrosis treated with ivacaftor: Data from national US and UK registries

(2019) Nataliya Volkova et al.   Journal of Cystic Fibrosis

In situ analysis reveals that CFTR is expressed in only a small minority of β-cells in normal adult human pancreas

(2019) Michael G White et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial

(2019) Harry G M Heijerman et al.   LANCET

Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele

(2019) Peter G. Middleton et al.   NEW ENGLAND JOURNAL OF MEDICINE

2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2020

(2019)   DIABETES CARE

Islet Interleukin-1β Immunoreactivity Is an Early Feature of Cystic Fibrosis That May Contribute to β-Cell Failure

(2018) Rebecca L. Hull et al.   DIABETES CARE

Effect of Lumacaftor/Ivacaftor on glucose metabolism and insulin secretion in Phe508del homozygous cystic fibrosis patients

(2018) Jan C. Thomassen et al.   Journal of Cystic Fibrosis

Disease-modifying drug therapy in cystic fibrosis

(2018) Katharine Harman et al.   Paediatric Respiratory Reviews

Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor

(2018) Leona Bessonova et al.   THORAX

Islet Hormone and Incretin Secretion in Cystic Fibrosis Following 4-months of Ivacaftor Therapy

(2018) Andrea Kelly et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Continuous glucose monitoring in youth with cystic fibrosis treated with lumacaftor-ivacaftor

(2018) Angel Li et al.   Journal of Cystic Fibrosis

ISPAD Clinical Practice Consensus Guidelines 2018 Compendium Management of cystic fibrosis related diabetes in children and adolescents

(2018) Antoinette Moran et al.   PEDIATRIC DIABETES

Insulin resistance: Review of the underlying molecular mechanisms

(2018) Habib Yaribeygi et al.   JOURNAL OF CELLULAR PHYSIOLOGY

CFTR Influences Beta Cell Function and Insulin Secretion Through Non-Cell Autonomous Exocrine-Derived Factors

(2017) Xingshen Sun et al.   ENDOCRINOLOGY

Combined Exercise Training Improves Glycemic Control in Adult with Cystic Fibrosis

(2017) NADIA BEAUDOIN et al.   MEDICINE AND SCIENCE IN SPORTS AND EXERCISE

Relationship between exercise capacity and glucose tolerance in cystic fibrosis

(2017) Karla Foster et al.   PEDIATRIC PULMONOLOGY

CFTR is involved in the regulation of glucagon secretion in human and rodent alpha cells

(2017) Anna Edlund et al.   Scientific Reports

CFTR potentiator therapy ameliorates impaired insulin secretion in CF patients with a gating mutation

(2016) Reuven Tsabari et al.   Journal of Cystic Fibrosis

Diabetes-related Mortality in Adults with Cystic Fibrosis. Role of Genotype and Sex

(2015) Connor Lewis et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Glycaemic regulation and insulin secretion are abnormal in cystic fibrosis pigs despite sparing of islet cell mass

(2015) Aliye Uc et al.   CLINICAL SCIENCE

Age- and Sex-Dependent Distribution of OGTT-Related Variables in a Population of Cystic Fibrosis Patients

(2015) Alberto Battezzati et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Clinical Updates in Cystic Fibrosis–Related Diabetes

(2015) Jennifer Beynon et al.   SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE

Lumacaftor alone and combined with ivacaftor: preclinical and clinical trial experience of F508del CFTR correction

(2015) John J. Brewington et al.   Expert Review of Respiratory Medicine

Resolution of Cystic Fibrosis–related Diabetes with Ivacaftor Therapy

(2014) Don Hayes et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

CFTR and Anoctamin 1 (ANO1) contribute to cAMP amplified exocytosis and insulin secretion in human and murine pancreatic beta-cells

(2014) Anna Edlund et al.   BMC Medicine

Glucose-induced electrical activities and insulin secretion in pancreatic islet β-cells are modulated by CFTR

(2014) Jing Hui Guo et al.   Nature Communications

Consensus statement for inert gas washout measurement using multiple- and single- breath tests

(2013) Paul D. Robinson et al.   EUROPEAN RESPIRATORY JOURNAL

Predictors for future cystic fibrosis-related diabetes by oral glucose tolerance test

(2013) Kerstin Schmid et al.   Journal of Cystic Fibrosis

Insulin secretion improves in cystic fibrosis following ivacaftor correction of CFTR: a small pilot study

(2013) Melena D Bellin et al.   PEDIATRIC DIABETES

Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations

(2012) Philip H. Quanjer et al.   EUROPEAN RESPIRATORY JOURNAL

Abnormal endocrine pancreas function at birth in cystic fibrosis ferrets

(2012) Alicia K. Olivier et al.   JOURNAL OF CLINICAL INVESTIGATION

Cystic Fibrosis-Related Diabetes: Current Trends in Prevalence, Incidence, and Mortality

(2009) A. Moran et al.   DIABETES CARE